Your search for major depressive disorder returned 47 results

Researchers sought to address the possible link between cognitive or mood symptoms and statins.

The Food and Drug Administration (FDA) has granted Fast Track designation to an investigational intranasal formulation of racemic ketamine for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder.

Some nutrient supplements may be beneficial as adjunctive treatment for common mental health condition.

Transcranial magnetic stimulation (TMS) uses magnetic fields to stimulate nerve cells in the brain.

Lundbeck announced that the FDA has approved a sNDA for Trintellix to include data regarding improved processing speed.

For adults with bipolar depression, tDCS seems to be safe and effective as an add-on intervention.

The FDA has cleared Nexstim’s NBT system for the treatment of major depressive disorder.

Escitalopram may be better for the treatment of depression than tDCS.

Prescriptions for benzodiazepine lasting 2-3 months or more and marked dose increases should be avoided.

Time spent on mobile phones and social media may contribute to the rise in depression.

HIV-infected adults with major depressive disorder have a 30% increased risk for acute myocardial infarction.

Sixty percent of patients responded to treatment.

The drug was found to work quickly in patients with clinical major depression.

The device is used to condition the patient to reduce or stop their aggressive behavior.

Screening recommended for those aged 12 to 18, however there is insufficient evidence to assess for children aged 11 and younger.

Changes were more pronounced in depressed volunteers.

There was insufficient evidence to recommend screening in children aged 11 and younger.